QUIMUNSA is a Spanish biotechnology company that provides solutions for real-life challenges in environmental health. The company was founded in 1962 and has since evolved into a leader in its industry, boasting a 11,000 m² industrial complex that includes a 300 m² R&D department and a 500 m² Marketing, Commercial, and Administrative department. QUIMUNSA has developed over 500 product references in its R&D department and holds 200 Official Homologations.
The company has implemented rigorous quality systems, including compliance with Good Manufacturing Practices (GMP'S), ISO-9.001 certification for quality management systems, and ISO 45001:2018 for the design, manufacture, and marketing of biocidal products. Additionally, QUIMUNSA holds the AITIM Quality Seal and various authorizations related to pharmaceuticals, veterinary medicines, and animal hygiene products.
QUIMUNSA's recent growth is evidenced by a Private Equity Round investment in September 2021, led by ABE Capital Partners. This injection of capital reflects confidence in the company's market presence and potential for further expansion.